Barbara Ryan - 04 Jun 2026 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Director
Issuer ticker: INKT
Reported as of: 04 Jun 2026
Net transaction value: -$19,141
SEC form: 4
Accepted by SEC: 05 Jun 2026, 18:04:03 UTC
Prior SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Melissa Orilall as Attorney-in-Fact for Barbara Ryan

Key filing fact

Barbara Ryan filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 05 Jun 2026.

Key facts

This page summarizes Barbara Ryan's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 05 Jun 2026, 18:04.

Change

Previous filing in this sequence was filed on 14 May 2026.
Current net transaction value: -$19,141.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001827169 Primary reporting owner

Ryan Barbara

Relationship: Director
Address: 149 FIFTH AVENUE, SUITE 500, NEW YORK
Signature: By: /s/ Melissa Orilall as Attorney-in-Fact for Barbara Ryan
Signature date: 04 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INKT transaction

Common Stock

Sale

Transaction value: $6,342
Shares: -500
Change %: -2.1%
Price: $12.68
Shares after: 22,969
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

INKT transaction

Common Stock

Sale

Transaction value: $12,800
Shares: -1,000
Change %: -4.4%
Price: $12.80
Shares after: 21,969
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.